2-(3,4-二氢异喹啉-2(1H)-基)乙醇 | 88014-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 2-(3,4-二氢异喹啉-2(1H)-基)乙醇
• 英文名称: 2-(3,4-dihydro-1H-isoquinolin-2-yl)-ethanol
• 英文别名: N-(2-hydroxyethyl)-1,2,3,4-tetrahydro-isoquinoline；2-(3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-ol；2-<2-Hydroxy-ethyl>-1,2,3,4-tetrahydro-isochinolin；2-(3,4-Dihydroisoquinolin-2(1H)-yl)ethanol；2-(3,4-dihydro-1H-isoquinolin-2-yl)ethanol
• CAS: 88014-15-7
• 化学式: C₁₁H₁₅NO
• mdl: MFCD08059809
• 分子量: 177.246
• InChiKey: WLRXAYDWKJAYPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  2-(3,4-二氢异喹啉-2(1H)-基)乙醇 在 四乙基对甲苯磺酸铵 、 亚磷酸二乙酯 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以38%的产率得到2-(2-Hydroxyethyl)-3,4-dihydro-isocarbostyril
  参考文献：
  名称：

  亚磷酸二乙酯促进四氢异喹啉电化学氧化为 3,4-二氢异喹啉-1(2H)-酮

  摘要：

  已开发出一种亚磷酸二乙酯介导的电化学氧化策略，用于在温和条件下从四氢异喹啉合成 3,4-二氢异喹啉-1(2H)-酮。该协议为在未分割的单元格中构建 C=O 键提供了一种环保且简单的方法。

  DOI：

  10.1055/s-0039-1690704
• 作为产物：
  描述：

  异喹啉 在 盐酸 、 tin 作用下， 生成 2-(3,4-二氢异喹啉-2(1H)-基)乙醇
  参考文献：
  名称：

  Slomka; Schueler, Journal of the American Pharmaceutical Association (1912), 1951, vol. 40, p. 47,49

  摘要：

  DOI：

文献信息

• Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists
  申请人：SmithKline Beecham S.p.A.

  公开号：US20020068827A1

  公开（公告）日：2002-06-06

  A compound of formula (I): 1 or a salt thereof, or a solvate thereof, wherein, Ar is an optionally substituted aryl or a C 5-7 cycloalkdienyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C 1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C 1-6 alkyl, amino C 1-6 alkyl, C 1-6 alkylaminoalkyl, di C 1-6 alkylaminoalkyl, C 1-6 acylaminoalkyl, C 1-6 alkoxyalkyl, C 1-6 alkylcarbonyl, carboxy, C 1-6 alkoxycarbonyl, C 1-6 alkoxycarbonyl C 1-6 alkyl, aminocarbonyl, C 1-6 alkylaminocarbonyl, di C 1-6 alkylaminocarbonyl, halogeno C 1-6 alkyl; or R is a group —(CH 2 ) p — wherein p is 2 or 3 which group forms a ring with a carbon atom of Ar; R 1 represents hydrogen or up to four optional subtitutents selected from the list consisting of: C 1-6 alkyl, C 1-6 alkenyl, aryl, C 1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C 1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono- and di-C 1-6 alkylamino; R 2 represents hydrogen, C 1-6 -alkyl, hydroxy, halogen, cyano, amino, mono- or di-C 1-6 -alkylamino, alkylsulphonylamino, mono- or di-C 1-6 -alkanoylamino wherein any alkyl group is optionally substituted with an amino group or with a mono- or di-alkylamino group, or R 2 is a moiety —X—(CH 2 ) n —Y wherein X is a bond or —O— and n is an integer in the range of from 1 to 5 providing that when X is —O— n is only an integer from 2 to 5 and Y represents a group NY 1 Y 2 wherein Y 1 and Y 2 are independently selected from hydrogen, C 1-6 -alkyl, C 1-6 -alkenyl, aryl or aryl-C 1-6 -alkyl or Y is hydroxy, halogen or an optionally substituted N-linked single or fused ring, heterocyclic group, R 3 is branched or linear C 1-6 alkyl, C 3-7 cycloalkyl, C 4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R 4 represents hydrogen or C 1-6 alkyl; a process for the preparation of such a compound, a pharmaceutical compositon containing such a compound and the use of such a compound or composition in medicine.

  一个式为（I）的化合物： 或其盐，或其溶剂合物，其中，Ar是可选择取代的芳基或C 5-7 环烯烃基团，或可选择取代的单个或融合环芳香杂环基团； R是C 1-6 烷基，C 3-7 环烷基，C 3-7 环烷基烷基，可选择取代的苯基或苯基C 1-6 烷基，可选择取代的含有最多四个来自O和N的杂原子的五元杂芳环，羟基C 1-6 烷基，氨基C 1-6 烷基，C 1-6 烷基氨基烷基，二C 1-6 烷基氨基烷基，C 1-6 酰胺基烷基，C 1-6 烷氧基烷基，C 1-6 烷基羰基，羧基，C 1-6 烷氧羰基，C 1-6 烷氧羰基C 1-6 烷基，氨基羰基，C 1-6 烷基氨基羰基，二C 1-6 烷基氨基羰基，卤代C 1-6 烷基；或R是一个基团—(CH 2 ) p —其中p为2或3，该基团与Ar的一个碳原子形成环； R 1 代表氢或来自以下列表中选择的最多四个可选取代基：C 1-6 烷基，C 1-6 烯基，芳基，C 1-6 烷氧基，羟基，卤素，硝基，氰基，羧基，羧胺基，磺胺基，C 1-6 烷氧羰基，三氟甲基，酰氧基，邻苯二甲酰胺基，氨基或单-和双-C 1-6 烷基氨基； R 2 代表氢，C 1-6 -烷基，羟基，卤素，氰基，氨基，单-或双-C 1-6 -烷基氨基，烷基磺酰氨基，单-或双-C 1-6 -酰胺基，其中任何烷基基团可选择地取代为氨基基团或单-或双-烷基氨基基团，或R 2 是一个基团—X—(CH 2 ) n —Y，其中X是键或—O—，n是在1到5范围内的整数，要求当X为—O—时，n仅为2到5之间的整数，Y代表一个基团NY 1 Y 2 ，其中Y 1 和Y 2 分别选择自氢，C 1-6 -烷基，C 1-6 -烯基，芳基或芳基-C 1-6 -烷基，或Y为羟基，卤素或可选择取代的N-连接的单个或融合环杂环基团， R 3 是支链或直链C 1-6 烷基，C 3-7 环烷基，C 4-7 环烷基烷基，可选择取代的芳基，或可选择取代的单个或融合环芳香杂环基团；和 R 4 代表氢或C 1-6 烷基；一种制备这种化合物的方法，含有这种化合物的药物组合物以及这种化合物或组合物在医学中的用途。
• Electrooxidative Cyclization of Hydroquinolyl Alcohols, Hydroquinolylamines, and Dimethyl Aminomalonates
  作者：Mitsuhiro Okimoto、Takashi Yoshida、Masayuki Hoshi、Kazuyuki Hattori、Masashi Komata、Kaori Numata、Kenta Tomozawa

  DOI：10.1071/ch07010

  日期：——

  Several hydroquinolyl alcohols and amines were electrochemically oxidized in methanol in the presence of sodium methoxide and potassium iodide to afford the corresponding intramolecular cyclization products. Furthermore, several amino malonates were electrochemically oxidized to yield the corresponding heterocyclic compounds through an intramolecular carbon–carbon bond formation in the presence of sodium cyanide in methanol.

  在甲醇中，在甲醇钠和碘化钾的存在下，几种氢醌醇和胺被电化学氧化，得到相应的分子内环化产物。此外，在甲醇中氰化钠存在下，几种丙二酸氨基酯通过分子内碳-碳键形成的电化学氧化作用生成了相应的杂环化合物。
• [EN] MEDICAMENTS<br/>[FR] MÉDICAMENTS
  申请人：MOTAC NEUROSCIENCE LTD

  公开号：WO2009056805A1

  公开（公告）日：2009-05-07

  A compound of formula (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.

  描述了一种化合物的化学式(I)：其中R1和R2如文本中定义的那样，这些化合物旨在用于治疗以多巴胺受体活性失衡为特征的医疗状况。
• α-Amino Acid Phenolic Ester Derivatives:  Novel Water-Soluble General Anesthetic Agents Which Allosterically Modulate GABA_A Receptors
  作者：Alison Anderson、Delia Belelli、D. Jonathan Bennett、Kirsteen I. Buchanan、Anna Casula、Andrew Cooke、Helen Feilden、David K. Gemmell、Niall M. Hamilton、Edward J. Hutchinson、Jeremy J. Lambert、Maurice S. Maidment、Ross McGuire、Petula McPhail、Susan Miller、Annalisa Muntoni、John A. Peters、Francis H. Sansbury、Donald Stevenson、Hardy Sundaram

  DOI：10.1021/jm010903i

  日期：2001.10.1

  In the search for a novel water-soluble general anesthetic agent the activity of an alpha-amino acid phenolic ester lead, identified from patent literature, was markedly improved. In addition to improving in vivo activity in mice, good in vitro activity at GABA(A) receptors was also conferred. Within the series of compounds good enantioselectivity for both in vitro and in vivo activity was found, supporting

  在寻找新型水溶性全身麻醉剂时，从专利文献中鉴定出的α-氨基酸酚酯铅的活性被显着提高。除了改善小鼠体内活性外，还赋予GABA（A）受体良好的体外活性。在该系列化合物中，发现体内和体外活性均具有良好的对映选择性，这支持了蛋白质介导的麻醉作用机制，涉及GABA（A）受体的变构调节。选择α-氨基酸酚酯19作为氢溴酸盐Org 25435，是因为它保留了最佳的整体麻醉特性，并具有改善的稳定性和水溶性，因此被选作临床评估。
• [EN] HETEROCYCLIC COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET AGENTS D'IMAGERIE POUR L'IMAGERIE DE LA PROTÉINE HUNTINGTINE
  申请人：CHDI FOUNDATION INC

  公开号：WO2021252775A1

  公开（公告）日：2021-12-16

  Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, especially huntingtin protein aggregation, compositions thereof, and methods of their use.

  本文提供了用于检测与蛋白聚集相关的疾病或病况，特别是与亨廷顿蛋白聚集相关的某些化合物和成像剂，以及它们的组合物和使用方法。